Hypersensitivity, Delayed
"Hypersensitivity, Delayed" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An increased reactivity to specific antigens mediated not by antibodies but by cells.
| Descriptor ID |
D006968
|
| MeSH Number(s) |
C20.543.418
|
| Concept/Terms |
Hypersensitivity, Delayed- Hypersensitivity, Delayed
- Hypersensitivity, Type IV
- Hypersensitivities, Type IV
- Type IV Hypersensitivities
- Delayed Hypersensitivity
- Delayed Hypersensitivities
- Hypersensitivities, Delayed
- Type IV Hypersensitivity
- Hypersensitivity, Tuberculin-Type
- Hypersensitivities, Tuberculin-Type
- Hypersensitivity, Tuberculin Type
- Tuberculin-Type Hypersensitivities
- Tuberculin-Type Hypersensitivity
- Tuberculin Type Hypersensitivity
|
Below are MeSH descriptors whose meaning is more general than "Hypersensitivity, Delayed".
Below are MeSH descriptors whose meaning is more specific than "Hypersensitivity, Delayed".
This graph shows the total number of publications written about "Hypersensitivity, Delayed" by people in this website by year, and whether "Hypersensitivity, Delayed" was a major or minor topic of these publications.
![]()
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Hypersensitivity, Delayed" by people in Profiles.
-
A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg. 2011 Feb; 253(2):328-35.
-
Total lymphocyte count, hemoglobin, and delayed-type hypersensitivity as predictors of death and AIDS illness in HIV-1-infected women receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004 Apr 01; 35(4):383-92.
-
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001 Jan 01; 19(1):145-56.
-
Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000 Jan 07; 14(1):11-21.
-
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response. J Infect Dis. 2000 Jan; 181(1):358-63.
-
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998 Jul; 178(1):70-9.
-
Cell-mediated and humoral immune responses to cartilage antigenic components. Scand J Immunol. 1979; 9(1):39-44.
-
[The participation of phenol-(DOPA-)oxidase containing cells (POZ) with the delayed hypersensitivity. (Preliminary report) (author's transl)]. Acta Histochem. 1978; 63(2):271-5.